2
عمومی::
لکوسیت، گویچه سفید (لوکوسیت)
Once the white blood cells (leukocytes) (>3500/µl) respectively platelets (thrombocytes) (>100 000/µl) have increased again, treatment can be resumed - if necessary at a reduced dose - provided there are no overall adverse effects (see above) that prevent continuation of therapy.
rapid decrease in white blood cells (leukocytes) during treatment or development of a reduced white blood cell count (leukopenia; leukocyte count < 3500/µl), reduced number of platelets (thrombocytopenia; platelet count < 100 000/µl), inflammation of the oral mucosa, inflammation of the oesophagus or throat, inflammation of the mucous membranes, diarrhoea, ulceration and bleeding of the gastrointestinal mucosa, bleeding of any location, uncontrollable vomiting, as well as any other severe side effects occur (e.g. nervous system disorders, heart damage).
Once the changes in blood count have resolved (restoration of the leukocytes to at least 3500/µl, platelets to at least 100 000/µl), treatment may be resumed - if necessary at a reduced dose - provided there are no other side effects (see above) that prevent continuation of therapy.
Leukocytes < 3,500 or thrombocytes < 100,000 Suspend therapy until increase of leukocytes (≥ 3,500) and thrombocytes
(≥ 100,000) Leukocytes < 2,500 or thrombocytes < 75,000 Suspend therapy until increase of leukocytes (≥ 3,500) and thrombocytes (≥ 100,000) but for at least 3 weeks Suspension of therapy due to blood count changes
واژگان شبکه مترجمین ایران